Collecting samples to study hairy cell leukemia and develop new cancer treatments
A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment
This study is collecting samples from people with hairy cell leukemia and healthy volunteers to see if new treatments can be developed to better fight this type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1263 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | Moxetumomab, rituximab, trametinib, binimetinib, ibrutinib, chemotherapy |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT01087333 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect clinical samples from patients diagnosed with hairy cell leukemia and other blood cancers, as well as healthy volunteers. Researchers will gather blood, urine, lymph, and tumor tissue samples to analyze the molecular and clinical aspects of these diseases. The study focuses on developing new treatments using recombinant immunotoxins, which are designed to target and kill cancer cells. By comparing samples from leukemia patients and healthy individuals, the study seeks to enhance understanding of these conditions and improve treatment options.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older diagnosed with hairy cell leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, or adult T cell lymphoma.
Not a fit: Patients with no history of hematologic malignancies or solid tumors, as well as those currently pregnant, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of more effective treatments for hairy cell leukemia and related blood cancers.
How similar studies have performed: Other studies have shown promise in using immunotoxins for treating hematologic malignancies, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: All participants * 18 years of age and older * Desire of the individual to submit data and samples for research * Ability to understand and the willingness to sign a written informed consent document. Individuals with cancer -Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission. Normal donors (Individuals without cancer) -Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor. EXCLUSION CRITERIA: All participants -Known pregnancy at enrollment. NOTE: A pregnancy test will be required in individuals on study prior to any procedure done for research purposes that is greater than minimal risk.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Robert J Kreitman, M.D. — National Cancer Institute (NCI)
- Study coordinator: Julie C Feurtado, R.N.
- Email: julie.feurtado@nih.gov
- Phone: (301) 480-6186
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.